May 5, 2015 – FDA Drug Safety Communication issued over increased risk of diabetic ketoacidosis with SGLT2 inhibitor diabetes drugs.
May 5, 2015 – FDA Drug Safety Communication issued over increased risk of diabetic ketoacidosis with SGLT2 inhibitor diabetes drugs.